Information
-
Trademark
-
97779170
-
International Classifications
-
Filing Date
February 03, 2023
a year ago
-
Transaction Date
January 25, 2024
5 months ago
-
Status Date
November 07, 2023
7 months ago
-
Location Date
November 07, 2023
7 months ago
-
Status Code
641
-
Current Location
TMO LAW OFFICE 129 - EXAMINING ATTORNEY ASSIGNED
Employee Name
LEE, DOUGLAS M
-
Attorney Docket Number
034845.375
Attorney Name
Scott D. Woldow
Law Office Assigned Location Code
O20
-
Owners
Mark Drawing Code
4000
Mark Identification
WONHAVEO
Case File Statements
- GS0051: Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; antibodies
Case File Event Statements
-
1/25/2024 - 5 months ago
7 - TEAS RESPONSE TO OFFICE ACTION RECEIVED
Type: TROA
-
11/7/2023 - 7 months ago
6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED
Type: GNRN
-
11/7/2023 - 7 months ago
5 - NON-FINAL ACTION E-MAILED
Type: GNRT
-
11/7/2023 - 7 months ago
4 - NON-FINAL ACTION WRITTEN
Type: CNRT
-
11/1/2023 - 8 months ago
3 - ASSIGNED TO EXAMINER
Type: DOCK
-
2/22/2023 - a year ago
2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Type: NWOS
-
2/7/2023 - a year ago
1 - NEW APPLICATION ENTERED
Type: NWAP